1)Aide N, Cappele O, Bottet P, et al:Efficiency of[(18)F]FDG PET in characterising renal cancer and detecting distant metastases:a comparison with CT. Eur J Nucl Med Mol Imaging 30:1236-1245, 2003
2)Kang DE, White RL Jr, Zuger JH, et al:Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 171:1806-1809, 2004
3)Majhail NS, Urbain JL, Albani JM, et al:F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J Clin Oncol 21:3995-4000, 2003
4)Namura K, Minamimoto R, Yao M, et al:Impact of maximum standardized uptake value(SUVmax)evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography(18F-FDG-PET/CT)on survival for patients with advanced renal cell carcinoma:a preliminary report. BMC Cancer 10:667, 2010
5)Nakaigawa N:Impact of maximum standardized uptake value(SUVmax)evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography(18F-FDG-PET/CT)on survival for patients with advanced renal cell carcinoma. ASCO J Clin Oncol 30(suppl 15 abstr 4626), 2012
6)Minamimoto R, Nakaigawa N, Tateishi U, et al:Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT. Clin Nucl Med 35:918-923, 2010
7)Ueno D, Yao M, Tateishi U, et al:Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer 12:162, 2012
8)Lyrdal D, Boijsen M, Suurküla M, et al:Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun 30:519-524, 2009
9)Vercellino L, Bousquet G, Baillet G, et al:18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma:preliminary study. Cancer Biother Radiopharm 24:137-144, 2009
10)Kayani I, Avril N, Bomanji J, et al:Sequential FDG-PET/CT as a biomarker of response to sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 17:6021-6028, 2011